Global C5 Complement Inhibitor Market is projected to reach US$ 298.88 billion by 2033

Global C5 Complement Inhibitor Market was valued at USD 10.2 billion in 2025 and is projected to reach US$ 298.88 billion by 2033, at a CAGR of 16.8% during the forecast period. Global C5 Complement Inhibitor Market focuses on therapies that block the complement protein C5, a key player in immune response and inflammation. These inhibitors, such as eculizumab and raflizumab , are crucial in treating rare conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) . Driven by rising chronic disease prevalence, increased R&D, and advancements in biologics, the market is expected to witness steady growth through 2033. Key regions include North America, Europe, and Asia-Pacific , with Alexion Pharmaceuticals as a leading player. However, the market faces challenges like high drug development costs, regulatory hurdles, and patent expirations. Click for free PDF Sample Report: https://prospectresearchreports.com/report/432532?type=reque...